Synonyms: IMP-4297 | IMP4297
Compound class:
Synthetic organic
Comment: Senaparib (IMP4297) is an oral PARP1 inhibitor that is being developed in a joint venture between IMPACT Therapeutics and Junshi Biosciences, for the treatment of BRCA-mutated solid tumours. It is one of the chemical structures claimed in patent WO2012130166A1 [1].
|
|
Bioactivity Comments |
We have been unable to identify activity data from peer-reviewed literature or patents. |